XTL Biopharmaceuticals Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.9202
- Today's High:
- $0.9621
- Open Price:
- $0.9202
- 52W Low:
- $0.75
- 52W High:
- $1.54
- Prev. Close:
- $0.95
- Volume:
- 403
Company Statistics
- Market Cap.:
- $5.18 million
- Book Value:
- 0.5
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -12.2%
- Return on Equity TTM:
- -68.88%
Company Profile
XTL Biopharmaceuticals Ltd ADR had its IPO on 2005-09-01 under the ticker symbol XTLB.
The company operates in the Healthcare sector and Biotechnology industry. XTL Biopharmaceuticals Ltd ADR has a staff strength of 0 employees.
Stock update
Shares of XTL Biopharmaceuticals Ltd ADR opened at $0.92 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.92 - $0.96, and closed at $0.96.
This is a +1.27% increase from the previous day's closing price.
A total volume of 403 shares were traded at the close of the day’s session.
In the last one week, shares of XTL Biopharmaceuticals Ltd ADR have slipped by -0.81%.
XTL Biopharmaceuticals Ltd ADR's Key Ratios
XTL Biopharmaceuticals Ltd ADR has a market cap of $5.18 million, indicating a price to book ratio of 1.4587 and a price to sales ratio of 0.
In the last 12-months XTL Biopharmaceuticals Ltd ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-842000. The EBITDA ratio measures XTL Biopharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, XTL Biopharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -12.2% with a return of equity of -68.88%.
In Q2, XTL Biopharmaceuticals Ltd ADR’s quarterly earnings growth was a negative -76% while revenue growth was a positive 0%.
XTL Biopharmaceuticals Ltd ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XTL Biopharmaceuticals Ltd ADR’s profitability.
XTL Biopharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.5778. Its price to sales ratio in the trailing 12-months stood at 0.
XTL Biopharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.88 million
- Total Liabilities
- $163000.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
XTL Biopharmaceuticals Ltd ADR ended 2024 with $2.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $2.88 million while shareholder equity stood at $2.72 million.
XTL Biopharmaceuticals Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $163000.00 in other current liabilities, 14120000.00 in common stock, $-157748000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.59 million and cash and short-term investments were $2.38 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
XTL Biopharmaceuticals Ltd ADR’s total current assets stands at $2.50 million while long-term investments were $0 and short-term investments were $794000.00. Its net receivables were $0 compared to accounts payable of $163000.00 and inventory worth $0.
In 2024, XTL Biopharmaceuticals Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, XTL Biopharmaceuticals Ltd ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.96
- 52-Week High
- $1.54
- 52-Week Low
- $0.75
- Analyst Target Price
- $
XTL Biopharmaceuticals Ltd ADR stock is currently trading at $0.96 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.92 and 200-day moving average was $1.18 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.
Around 1444.8% of the company’s stock are held by insiders while 458% are held by institutions.
Frequently Asked Questions About XTL Biopharmaceuticals Ltd ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.